🇺🇸 FDA
Patent

US 8263549

C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors

granted A61KA61K38/00A61P

Quick answer

US patent 8263549 (C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K38/00, A61P, A61P31/12